According to the Zhitong Finance App, Nuocheng Jianhua (09969) announced the results for the first three quarters of 2026. The company's total revenue was 2,099 billion yuan, an increase of 88.21% over the same period last year. Among them, pharmaceutical sales revenue was 1,449 billion yuan, an increase of 41.47% over the same period last year. The main reason for the increase in revenue was the continued release of the core product obutinib, additional sales contributions of tamxitumab and zoletriptinib, and the completion of subsequent milestone deliveries in the licensing agreement between the company and Zenas BioPharma, Inc. Net profit attributable to shareholders of listed companies was approximately 656 million yuan, turning a year-on-year loss into a profit.

From January to September 2026, the net cash flow from the company's operating activities was 220 million yuan, which changed from negative to positive over the previous year. Mainly due to increased revenue from drug sales and licensing, the company's operating cash flow situation continued to improve.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.